

AMENDMENTS TO THE CLAIMS

1-5. (Canceled)

6. (Currently Amended) A fusion polypeptide, comprising an amino acid sequence ~~derived from a non-VGF protein gene fused to~~ covalently linked to an the amino acid sequence as set forth in of SEQ ID NO: 7.

7. (Currently Amended) The fusion polypeptide of Claim 6, wherein the amino acid sequence ~~derived from a non-VGF gene encodes~~ from a non-VGF protein is an amino acid sequence of an IgG constant domain or fragment thereof.

8. (Previously Presented) A composition comprising the polypeptide of Claim 6 and a pharmaceutically acceptable formulation agent.

9. (Original) The composition of Claim 8 wherein the pharmaceutically acceptable formulation agent is a carrier, adjuvant, solubilizer, stabilizer, or anti-oxidant.

10-11. (Canceled)

12. (Currently Amended) The polypeptide of Claim 6, which is covalently modified with a water-soluble polymer, ~~that~~ wherein the water-soluble polymer is polyethylene glycol, monomethoxy-polyethylene glycol, dextran, cellulose, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols, or polyvinyl alcohol.

13. (Previously Amended) The polypeptide of Claim 12 wherein the water-soluble polymer is polyethylene glycol or dextran.

14-21. (Canceled)